docetaxel + gemcitabine + vinorelbine

This is a combination chemotherapy regimen consisting of three small molecule cytotoxic agents—docetaxel, gemcitabine, and vinorelbine. It is used primarily in the treatment of advanced non-small-cell lung cancer (NSCLC), particularly as a non-platinum-based alternative to standard platinum-containing regimens. The typical protocol involves sequential administration, with patients receiving gemcitabine and vinorelbine together for several cycles followed by docetaxel for additional cycles. Each drug has a distinct mechanism of action targeting different aspects of cell division or DNA synthesis: - Docetaxel stabilizes microtubules and inhibits their depolymerization, disrupting mitosis. - Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporation into DNA and inhibition of ribonucleotide reductase. - Vinorelbine disrupts microtubule assembly by binding to tubulin, inhibiting mitosis. This triplet regimen has been studied in phase II and III clinical trials for efficacy and toxicity compared to standard treatments in NSCLC[1][2][5].